Coherus announces positive phase 2b efficacy data on novel oral therapy
Coherus BioSciences announced that a study with CHS-131 in treatment-naïve, relapsing remitting multiple sclerosis subjects demonstrated approximately a 50% decrease in the incidence of new contrast-enhancing lesions over six months when compared to placebo. June 28, 2016